NCT01807156View on ClinicalTrials.gov

Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Hepatocellular Cancer
Interventions
DRUG

Tivozanib

Oral medication given daily. No placebo.

Trial Locations (1)

30322

Emory University, Winship Cancer Institute, Atlanta

Sponsors
All Listed Sponsors
collaborator

AVEO Pharmaceuticals, Inc.

INDUSTRY

lead

Emory University

OTHER